ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses

Chen, Wensheng; Chen, Jiezhen; Wang, Yuanping; Yan, Jiaqi; Yan, Xia; Wang, Dawei*; Liu, Yuntao*广东省人民医院; 广州医学院; 广州中医药大学; 1
Frontiers in Cardiovascular Medicine2022-10-24DOI: 10.3389/fcvm.2022.1001072
3被引8阅读
引用收藏
分享

摘要

Objectives: Evidence from systematic reviews/meta-analyses about the efficacy and safety of Qishen Yiqi (QSYQ) dripping pills in chronic heart failure (CHF) remains unclear. This study comprehensively reviewed available systematic reviews on latest evidence to provide reliable information for the clinical use of QSYQ in CHF. Methods: The systematic review was performed on studies retrieved from six major medical databases. Eligible studies were evaluated in terms of methodological quality and quality of evidence using the Assessment of Multiple Systematic review 2 (AMSTAR-2) tool, the Risk of Bias in Systematic Reviews (ROBIS) was used to assess the risk of bias, and the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) 2020 was utilized for assessing reporting quality. In addition, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to determine primary outcome indicators' evidence quality. Results: A total of 14 systematic reviews were included in this study, based on which it could be concluded that QSYQ combined with conventional medicine (CM) treatment tended to be superior to CM treatment alone in terms of improving cardiac function-related indices (e.g., increasing the left ventricular ejection fraction [LVEF] and reducing the left ventricular end-diastolic dimension [LVEDD] and left ventricular end-systolic internal diameter [LVESD]), improving the total effective rate and 6-min walking distance (6MWD), and reducing N-terminal pro-brain natriuretic peptide (NT-proBNP). Overall, no serious QSYQ-related adverse events were observed. However, the GRADE results showed "very low " to "moderate " evidence for these outcomes, with no high-quality evidence supporting them. Unsatisfactory results were obtained in terms of methodological quality, risk of bias and reporting quality after assessment using the AMSTAR-2, ROBIS, and PRISMA 2020, limited mainly by deficiencies in the following areas: registration of study protocols, explanation of the inclusion of randomized controlled trials (RCTs), complete and detailed search strategy, list of excluded literature, description of funding sources for inclusion in RCTs, investigation of the impact of risk of bias on the results of meta-analysis, and reporting of potential conflicts of interest. Conclusion: The efficacy and safety of QSYQ adjuvant therapy in CHF remain to be further clarified due to the lack of high-quality evidence provided by current systematic reviews.

学科与关键词

关键词
Qishen Yiqi drop pillchronic heart failuresystematic reviewmeta-analysesoverview
相关
加载中…
  • A Critical Overview of Systematic Reviews of Shenfu Injection for Heart Failure
    Huang, Jinke; Wang, Yanlu; Huang, Suihe; Qin, Xiaohui; Yan, Fang; Shen, Min; Huang, Yong*Cardiovascular Therapeutics, 2021, 2021: 8816590.被引 9
  • A Systematic Review and Meta-Analysis of the Efficacy and Safety of Xinbao Pill in Chronic Heart Failure
    Wang, Yuanping; Liu, Yuntao; Liu, Zhongqiu; Cheng, Yuanyuan*; Wang, Dawei*Frontiers in Pharmacology, 2022, 13: 846867.被引 4
  • Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure
    Hui, Guan; Guohua, Dai; Lili, Ren; Wulin, Gao; Haoran, Fu; Zepeng, Zhao; Xin, Liu; Jue, LiMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(2): e24285.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Cardiovascular Medicine
发表日期
2022-10-24
卷期
第 9 卷
页码
1001072
DOI
10.3389/fcvm.2022.1001072
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Guangzhou Science and Technology Project; Guangdong Basic and Applied Basic Research Foundation; Key-Area Research and Development Program of Guangdong Province; [82174156]; [202002030432]; [2022A1515011701]; [2020B1111100004]

作者

  • C

    Chen, Wensheng (第一作者)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • C

    Chen, Jiezhen

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 7 位作者收起作者
  • W

    Wang, Yuanping

    guangzhou univ chinese med

  • Y

    Yan, Jiaqi

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Y

    Yan, Xia

    2 · guangdong prov hosp · guangzhou univ chinese med

  • W

    Wang, Dawei (通讯)

    guangzhou univ chinese med · 1 · med coll guangzhou

  • L

    Liu, Yuntao (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417